Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lowered its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 288,083 shares of the company's stock after selling 41,481 shares during the period. Envestnet Asset Management Inc. owned 0.34% of Progyny worth $4,969,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. River Road Asset Management LLC purchased a new stake in Progyny during the fourth quarter worth about $25,529,000. Pacer Advisors Inc. raised its position in Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after acquiring an additional 1,183,558 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after acquiring an additional 695,740 shares during the period. Barclays PLC boosted its position in shares of Progyny by 530.4% during the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock worth $11,835,000 after purchasing an additional 594,140 shares in the last quarter. Finally, Baillie Gifford & Co. grew its stake in shares of Progyny by 52.2% during the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock worth $22,989,000 after purchasing an additional 456,853 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Bank of America raised their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research report on Monday, March 31st. Finally, Canaccord Genuity Group raised their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Progyny currently has an average rating of "Hold" and a consensus price target of $23.64.

Progyny Price Performance

Shares of Progyny stock opened at $21.87 on Wednesday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 37.71, a P/E/G ratio of 2.39 and a beta of 1.33. The stock has a 50-day simple moving average of $21.93 and a 200-day simple moving average of $18.94. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $33.84.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.